Your browser doesn't support javascript.
loading
Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
Kanematsu-Yamaki, Yoko; Nishizawa, Naoki; Kaisho, Tomoko; Nagai, Hiroaki; Mochida, Taisuke; Asakawa, Tomoko; Inooka, Hiroshi; Dote, Katsuko; Fujita, Hisashi; Matsumiya, Kouta; Hirabayashi, Hideki; Sakamoto, Junichi; Ohtaki, Tetsuya; Takekawa, Shiro; Asami, Taiji.
Afiliación
  • Kanematsu-Yamaki Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Nishizawa N; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Kaisho T; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Nagai H; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Mochida T; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Asakawa T; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Inooka H; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Dote K; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Fujita H; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Matsumiya K; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Hirabayashi H; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Sakamoto J; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Ohtaki T; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Takekawa S; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
  • Asami T; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd. , Fujisawa, 251-8555, Japan.
J Med Chem ; 60(14): 6089-6097, 2017 07 27.
Article en En | MEDLINE | ID: mdl-28657315
Neuromedin U (NMU) is a neuropeptide that mediates a variety of physiological functions via its receptors, NMUR1 and NMUR2. Recently, there has been an increased focus on NMU as a promising treatment option for diabetes and obesity. A short form of NMU (NMU-8) has potent agonist activity for both receptors but is metabolically unstable. Therefore, we designed and synthesized NMU-8 analogues modified by polyethylene glycol (PEG; molecular weight, 20 kDa; PEG20k) via a linker. 3-(2-Naphthyl)alanine substitution at position 19 increased NMUR2 selectivity of NMU-8 analogues with retention of high agonist activity. Compound 37, an NMUR2-selective PEG20k analogue containing piperazin-1-ylacetyl linker, exhibited a potent body weight-lowering effect with concomitant inhibition of food intake in a dose-dependent manner (body weight loss of 12.4% at 30 nmol/kg) by once-daily repeated dosing for 2 weeks in mice with diet-induced obesity.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Polietilenglicoles / Neuropéptidos / Receptores de Neurotransmisores / Fármacos Antiobesidad / Obesidad Límite: Animals Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Polietilenglicoles / Neuropéptidos / Receptores de Neurotransmisores / Fármacos Antiobesidad / Obesidad Límite: Animals Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Japón